SP-0021: Generation of density maps for dose calculations from MRI using atlas methods  by Greer, P.B. et al.
3rd ESTRO Forum 2015              S11 
Conclusions: Both DWI and 18F-FDG PET/CT are useful tools 
to identify those patients who are candidates for a wait and 
see policy or a local excision. We hope to improve the 
predictive value of functional imaging by integrating them 
with molecular markers. 
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The use of imaging is a crucial part of radiotherapy (RT), and 
it is used to localize both tumours and sensitive organs. 
Imaging is also the input to treatment planning calculations 
and for patient set-up. Magnetic resonance (MR) imaging 
provides excellent soft tissue contrast, and it also offers 
functional information of the tissues. Therefore, a major 
argument for replacing CT with MR in the RT process is the 
significantly improved spatial definition of target and risk 
organ volumes. However, in order to fully integrate MR into 
the RT workflow, CT-information also needs to be replaced 
by MR-data for accurate dose calculations and generation of 
reference images for patient positioning. Accordingly, the 
MR-only scenario in RT requires a substantial amount of 
research, development and hard work, before it can be 
brought into clinical practice. 
In Sweden, we have addressed the task by a national network 
called the “Gentle Radiotherapy” project, which was 
initiated in 2014. The aims of the project are to facilitate a 
fully integrated MR in the workflow of RT, and to promote 
the use of MR in clinical studies. The project is supported by 
the “Swedish Innovation Agency” (VINNOVA). The members of 
the consortium are six University Hospitals and six industrial 
partners. The work is divided into five dedicated work 
packages (WP): 1) Optimisation of sequences and protocols 
for RT applications, 2) MR-based treatment planning, 3) 
Image registration and automatic segmentation, 4) Q/A of 
MR-only workflow, and 5) ‘Functional MRI’ and clinical 
studies. About 50 researchers and clinicians are actively 
working in the five work packages, but even further scientists 
are involved. The mixture of clinical practice, academic 
science and industrial innovation creates a vibrant research 
environment. Besides the national project meetings, an 
educational series of web-based seminars on relevant topics 
of MR in RT is being developed. The expected final outcome 
of the project is clinical procedures, scientific research as 
well as new industrial products. The present status of the 
national Gentle radiotherapy project will be reviewed and a 
few results will be presented.  
In one subproject of Gentle Radiotherapy methods for 
creating CT equivalent data from MR-images are studied, i.e. 
synthetic CT images (sCT) for MR-only workflow. The 
Statistical Decomposition Algorithm (SDA) automatically 
decomposes and analyzes a standard type MRI image volume 
with respect to a plurality of tissue types, using a template 
assisted classification method. In a preliminary study, sCT 
images generated by the SDA were evaluated by comparing 
dosimetric accuracy between sCT and conventional CT for a 
set of six prostate tumor patients. Average mean absorbed 
dose difference to target was 0.1±0.2% (1 s.d.) between CT 
and sCT. Even with a restrictive gamma criteria (2% local 
dose/1mm), the pass rate was exceeding 99.9% in the 
transversal isocenter plane (superficial points excluded) for 
all cases. A study including more patients is in progress. This 
study is a good example of how an industrial partner works 
closely with academia/clinic in order to develop a new tool. 
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Introduction: Several different methods of mapping electron 
densities to MRI scans for dose calculation purposes have 
been proposed. These can be broadly grouped into 
classification based methods or atlas based methods. The 
classification methods estimate the tissue type from the MRI 
signal using single or multiple MRI scan sequences and assign 
an appropriate density. The atlas based methods use 
deformable image registration techniques to register single 
or multiple MRI atlas scans to a patient MRI scan and then 
assign densities. In this work a method that combines multi-
atlas deformable registration to the patient MR scan and 
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local weighted voting to assign a CT value to each voxel of 
the MR planning scan has been developed and tested.  
Methods: Forty men with ages ranging from 58 to 78 
undergoing prostate cancer radiation therapy treatment were 
scanned under a research protocol. Patients were positioned 
at MR in the treatment position on a Siemens Skyra 3T 
scanner. The planning MR sequence was a 3D, T2 weighted 
1.6 mm isotropic voxel SPACE sequence with field-of-view to 
cover the entire pelvis (ranging from 38 - 45 cm2) acquired in 
6 mins 40 s. All scans were contoured by 3 experienced 
observers. A conventional CT scan was acquired for the 
patient treatment plan, atlas generation, and to compare 
dose calculations.  
The atlas database is created by deformable registeration of 
the patient MR scan to the corresponding patient CT scan to 
form conjugate MR-CT pairs. To create synthetic CT scans 
from a subsequent patient planning MR scan the following 
steps are used: 1) each atlas MR scan is deformably 
registered to the patient planning MR scan; 2) for small voxel 
regions of the patient planning MR, the intensity is compared 
to the same voxel in all the registered atlas MR scans; 3) each 
atlas scan is assigned a weighting according to the similarity 
of the voxel values with the most similar having the highest 
weighting with all assigned weights summing to 1; 4) the CT 
values from the corresponding voxel of the conjugate CT 
atlas scans are added together using the previously 
determined weightings to provide the CT intensity value of 
that voxel of the synthetic CT scan.  
Results: Dose comparisons between the CT and synthetic CT 
scans created from the MR with the Eclipse AAA algorithm 
had an average difference of 0.3% and standard deviation of 
0.7% with tests performed using a leave-one-out approach. 
Gold fiducials are automatically segmented from MR scans 
(small field of view T1 flip 80 sequence) for image-guidance. 
Distortions and geometric accuracy of digitally reconstructed 
radiographs were tested with geometric phantoms and were 
within 1 mm of CT based values. 
Conclusions: MR-only planning using atlas-based electron 
density mapping to create synthetic CT scans for dose 
calculations has been shown to be an accurate method for 
prostate treatment planning. The method requires only a 
single conventional T2 weighted MR sequence. A prospective 
study using MR-only planning is currently in development to 
translate the MR-only workflow to clinical practice at our 
institution.  
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In a MR-only workflow, the planning CT scan used in the 
preparation of a radiotherapy treatment is replaced by MRI. 
MRI already outperforms CT in target and OAR definition in 
many cases, but for treatment planning the MRI is usually 
registered to a planning CT scan. For MR-only, the MRI scan is 
also needed for RT dose planning and image-guided 
radiotherapy at the treatment machine. The MR-only 
workflow allows us to abolish two preparation steps: the 
acquisition of the planning CT and the subsequent, 
registration of the planning CT with MRI. As the latter step 
can be inaccurate, the MR-only workflow improves both 
patient comfort and the accuracy of target localisation. 
For dose planning, electron densities now need to be derived 
from the MRI. Several methods have been developed for this 
purpose. One solution is to classify the tissue types in an MRI 
scan and assign Hounsfield Units (HU) accordingly. Errors in 
the Hounsfield Unit assignment can result in wrong dose 
deposition to both target and OAR. Therefore, QA of these 
scans is crucial for the RT chain. Since there is no CT scan 
available, the Hounsfield Unit map derived from MRI cannot 
be cross-checked with a regular planning CT. 
Although methods to derive a HU map from MRI are 
increasingly accurate, image artefacts in the MR scans 
themselves may corrupt the result. For example, an 
unnoticed paperclip in the scanner results in distorted MRI 
scans. For this reason, QA  has to be performed for each 
patient. Since this will be time-consuming, smart strategies 
are needed. 
In-vivo EPID dosimetry checks the consistency in the whole RT 
chain. Therefore, it is a suitable way to verify the integrity of 
the HU map derived from the MRI scan. The patient 
representation is checked by measuring transmission directly 
behind the patient with the EPID panel and comparing it with 
the calculated transmission from the MRI-derived HU map. 
The in-vivo EPID dosimetry method is fully automatic and 
easily performed for each individual patient. Furthermore, 
any significant under- or over dosage caused by an 
inconsistent HU assignment is reported in 3D. 
We tested the in-vivo dosimetry method for MR-only QA for 
the pelvic case. MR-only data was collected for prostate and 
rectum cancer patients on a Philips 3.0T MR system in 
treatment position on a flat table top. A 6-element phased-
array coil was strapped loosely on the pelvis to minimize 
body contour deformation. From the conventional MR DIXON 
scans, water and fat were classified. Bone was segmented 
with an atlas labelling technique into cortical bone and bone 
marrow. 
Subsequently, the clinical CT based VMAT plans were 
recalculated on MRI-derived HU maps with the same set of 
Monitor Units. The plans were compared using gamma 
evaluation and clinical dose parameters. 
In-vivo measured EPID dose of the first three fractions was 
back-projected to the patient in 3D. For the MR-only 
workflow the transmission was calculated from the MRI-
derived HU map. Dose differences were evaluated with a 3%-
3mm gamma criteria within the 50% isodose surface, 
consistent with our clinical practice. 
QA of a MR-only workflow is needed since errors in the MR-
derived HU maps directly effect dose distribution. In-vivo 
EPID dosimetry shows to be a promising method for QA of a 
MR-only workflow, since it checks the consistency in the 
whole RT chain in an automatic way. 
Symposium: Proton therapy I: future challenges 
SP-0023   
3D image and dose guidance 
L. Dong1 
1Scripps Proton Therapy Center, Medical Physics, San Diego, 
USA 
Abstract not received. 
SP-0024   
Current developments in proton and ion beam production 
and delivery 
O. Jäkel1 
1German Cancer Research Center, Medical Physics in 
Radiation Oncology, Heidelberg, Germany  
